Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9186977 | 0.87 | LDHA (0.59) | LDHAACACBMEN1KMT2AALDH1A1 | |
| SCHEMBL148634 | 0.84 | ABL1 (0.52) | LDHAMEN1KMT2AABL1RIN1 | |
| SCHEMBL17144912 | 0.77 | LDHA (0.60) | LDHAACACBMEN1KMT2AABL1 | |
| SCHEMBL23997386 | 0.76 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1MTNR1AMTNR1B | |
| SCHEMBL30336782 | 0.76 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1MTNR1AMTNR1B | |
| SCHEMBL16428955 | 0.74 | ALDH1A1 (0.51) | LDHAALDH1A1FOSTTRJUN | |
| SCHEMBL11300831 | 0.73 | LDHA (0.59) | LDHAACACBMEN1KMT2AALDH1A1 | |
| SCHEMBL14812349 | 0.73 | MTNR1A (0.60) | ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL28745588 | 0.73 | GAA (0.50) | LDHAMEN1KMT2AABL1RIN1 | |
| SCHEMBL27618563 | 0.73 | GABRA1 (0.52) | LDHAFOSTTRJUNNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | LDHA 4451/4885ACACB 4833/4885MEN1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.